Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
ConditionHCC
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChen Xiaoping
About this trial
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.
Eligibility criteria
Qualifiers
Aged 18-75.
No previous local or systemic treatment for hepatocellular carcinoma.
Child-Pugh liver function score ≤ 7.
ECOG PS 0-1.
Disqualifiers
Pregnant and lactating women.
Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).
A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication/esophageal varices), as determined by the investigator.
Active infection.
Trial design
Treatments tested in this trial
- PD-1 monoclonal antibody and lenvatinib
- PD-1 monoclonal antibody
Treatment groups
300 Participants
are divided into 2 treatment groupsSponsors and collaborators
Chen Xiaoping
Lead sponsor
Tongji Hospital
Sponsor institution
Source ClinicalTrials.gov